Baohuoside I powder 98%

Short Description:

Baohuoside is a rare natural flavonoid, mainly extracted from epimedium pubescens, epimedium grandiflorum, and other plants. disease, infectious diseases, and inflammation.


  • FOB Price: US $0.5 - 2000 / KG
  • Min.Order Quantity: 1 KG
  • Supply Ability: 10000 KG/per Month
  • Port: SHANGHAI/BEIJING
  • Payment Terms: L/C,D/A,D/P,T/T
  • :
  • Product Detail

    Product Tags

    Product Name:Baohuoside I powder 98%

    Botanic Source:Epimedium koreanum Nakai, Epimedium brevicornu Maxim

    CAS No:113558-15-9

    Other Name:Icariside-II, Icariin-II

    Specifications:≥98%

    Colour: Light Yellow powder with characteristic odor and taste

    GMO Status:GMO Free

    Packing: in 25kgs fiber drums

    Storage:Keep container unopened in cool, dry place,Keep away from strong light

    Shelf Life:24 months from date of production

     

    Baohuoside I is a flavonoid compound obtained from Epimedium koreanum. As an inhibitor of CXCR4, it can inhibit the expression of CXCR4, induce apoptosis, and has anti-tumor activity.

     

    Baohuoside powders are derived from Epimedium koreanum Nakai or Epimedium brevicornu Maxim, a herbal plant native to China, Asia. The Baohuoside manufacturing process begins with the raw material from the Epimedium plant being crushed and then extracted with ethanol. The extracted liquid is filtered and concentrated before diluting with water and undergoing enzymatic hydrolysis. Afterward, the substance is washed and parsed into ethanol, followed by concentration, solvent extraction, solvent recovery, crystallization, suction filtration, and drying which ultimately produces the Baohuoside powder 98% in its final powder form. Careful attention must be paid to each step during Baohuoside processing as their particular function helps create a product that can effectively retain its health benefits throughout its shelf life when stored properly. Ultimately Baohuoside manufacturing yields an important supplement with a range of positive effects on an individual’s health when used correctly.

     

     

    In Vitro Activity:Baohuoside I is an inhibitor of CXCR4 and downregulates CXCR4 expression at 12-25 μ M. Baohuoside I (0-25 μ M) inhibits NF – κ B activation in a dose-dependent manner and inhibits CXCL12 induced invasion of cervical cancer cells. Bohorside I also inhibit the invasion of breast cancer cells [1]. Baohuoside I inhibited A549 cell viability, with IC50 values of 25.1 μ M at 24 hours, 11.5 μ M, and 9.6 μ M at 48 hours and 72 hours, respectively. Bohorside I (25 μ M) inhibits the caspase cascade in A549 cells, increases ROS levels, and activates JNK and p38MAPK signaling cascades [2]. Boforseid I (3.125, 6.25, 12.5, 25.0, and 50.0 μ g/mL) significantly and dose-dependently blocked the growth of esophageal squamous cell carcinoma Eca109 cells, with an IC50 of 4.8 μ g/mL at 48 hours [3].

     

    In Vivo Activity:Baohuoside I (25 mg/kg) can reduce the levels of β - catenin protein in nude mice, The expression of cyclin D1 and survivin

     

    Cell experiments:

    The cytotoxic effect of Baohuoside I on A549 cells was determined by MTT assay. Inoculate cells (1 × 10 4 cells/well) into a 96 well plate and treat with Baohua glycoside I (6.25, 12.5, and 25 μ M) or 1mM NAC for 24, 48, or 72 hours. After removing the culture medium containing MTT, dissolve the formed crystals by adding DMSO to each well. After mixing, measure the absorbance of cells at 540 nm using the Multiskan Spectrum Microplate Reader [2].

     

    Animal experiments:

    Female Balb/c nude mice (4-6 weeks old) were used for measurement. Harvest Eca109 Luc cells from sub confluence and resuspend them in PBS until the final density is 2 × 107 cells/mL. Before injection, resuspend the cells in PBS and analyze them using the 0.4% trypan blue exclusion assay (live cells>90%). For subcutaneous injection, 1 × 107 Eca109 Luc cells from 200 μ LPBS were injected into the left abdomen of each mouse using a 27G needle. After one week of tumor cell injection, Boforside I (25mg/kg per mouse) was injected into the lesion once a day, while 10 mice used for vector therapy were given an equal volume of PBS [3].

     


  • Previous:
  • Next: